Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases member of CataloniaBio & HealthTech, today announces the completion of a Series B funding round of €21.3 million, the most important in the Catalan biotechnology sector so far this year.

The funding round was led by Fund+, joined by SRIW, SFPI-FPIM and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi Ventures, Caixa Capital Risc and HealthEquity).

“The proceeds of the round will allow the company to demonstrate the potential of MIN-102 in new indications,” said Marc Martinell, co-founder and CEO of Minoryx. “These indications for MIN-102 include neuroinflammatory conditions such as cerebral ALD (cALD) as well as multiple neurodegenerative diseases.”

Following this Series B funding round, two new members will join the Board of Directors of Minoryx: Philippe Monteyne and Gery Lefebvre, representing Fund+ and SRIW, respectively.

More information

Latest related news:

• Minoryx begins a phase II/III clinical study in patients with adrenomyeloneuropathy
• Minoryx spins off SEE-Tx platform into new company Gain Therapeutics
• Biomedical industry in Catalonia raises €102 million in investment in 2017

Photo: Marc Martinell, CEO of Minoryx and former member of CataloniaBio board (2014-2018) - © Minoryx